Elena Schartmann

Comparison of blood‐brain barrier penetration efficiencies between linear and cyclic all‐d‐enantiomeric peptides developed for the treatment of Alzheimer's disease

K. Langen, N. Shah, Nan Jiang, 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer’s Disease

K. Langen, N. Shah, D. Willbold, 2018, Journal of Alzheimer's disease : JAD.

Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer’s Mice with Full-blown Pathology

K. Langen, N. Shah, S. Hartwig, 2018, Molecular Neurobiology.

Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease.

N. Shah, J. Breitkreutz, K. Langen, 2016, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Blood-brain barrier penetration of an Aβ-targeted, arginine-rich, d-enantiomeric peptide.

N. Shah, T. van Groen, K. Langen, 2016, Biochimica et biophysica acta.

Development and validation of an UHPLC-ESI-QTOF-MS method for quantification of the highly hydrophilic amyloid-β oligomer eliminating all-D-enantiomeric peptide RD2 in mouse plasma.

D. Willbold, B. Buscher, B. Santiago-Schübel, 2018, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology

T. van Groen, I. Kadish, D. Willbold, 2017, Scientific Reports.

Pharmacokinetic Properties of a Novel d-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers

J. Breitkreutz, K. Langen, Nan Jiang, 2015, Pharmaceutical Research.

Pharmacokinetic Properties of a Novel d-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers

N. Shah, J. Breitkreutz, K. Langen, 2016, Pharmaceutical Research.

Oral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acid.

C. Zafiu, Markus Tusche, B. Santiago-Schübel, 2020, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology

T. van Groen, I. Kadish, D. Willbold, 2017, Scientific Reports.

Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease

N. Shah, J. Breitkreutz, K. Langen, 2015, PloS one.

Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2

K. Langen, N. Shah, D. Willbold, 2019, Neurobiology of Disease.